Monday, September 15, 2025

Latest

Revive Therapeutics Looks To Bring Bucillamine To India

Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum of understanding with that of Supriya Lifescience to bring Bucillamine to the country under an emergency use authorization to treat COVID-19.

The arrangement will see Supriya, whom is a specialty pharma firm within India, work with Revive to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India. Supriya is an EUGMP and USFDA approved manufacturer and supplier of active pharmaceutical products and ingredients, with exports to 78 separate countries.

The arrangement could also potentially lead to global commercialization of the drug, through the use of Supriya’s extensive manufacturing and commercial network in combination with the firms FDA phase 3 clinical trials. The firms manufacturing facilities are currently approved by over nine international regulatory authorities.

“While our Phase 3 clinical study for COVID-19 is ongoing in the USA, we  are laying the ground work by partnering with Supriya to execute on our global manufacturing and commercialization plans and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to. We are focused on completing our current Phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe, and Canada.”

Michael Frank, CEO of Revive

Revive Therapeutics last traded at $0.425 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study

Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase...

Friday, February 26, 2021, 08:54:19 AM

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded....

Thursday, March 5, 2020, 08:46:25 AM

Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials

Revive Therapeutics (CSE: RVV) (OTC: RVVTF) is one step closer to conducting its phase 3...

Friday, August 14, 2020, 08:50:35 AM

Revive Files Clinical Trial Application With Health Canada, Releases Phase 3 FDA Study Design For Potential Treatment Of COVID-19

Revive Therapeutics (CSE: RVV) continues to advance its clinical trial efforts. The company announced this...

Wednesday, June 3, 2020, 11:30:38 AM

Revive Files Pre-IND Meeting With FDA For COVID-19 Treatment

Revive Therapeutics (CSE: RVV) this morning announced that it has filed its pre-investigational new drug...

Friday, April 3, 2020, 10:44:10 AM